They concluded that the host immune system is indispensable for PD-1/PD-L1 blockade therapy, and the host DCs and macrophages-derived PD-L1, rather than cancer cell-intrinsic PD-L1, predominantly accounts for the blockade therapeutical efficacy. This evidence concerns the gene CD274 and cancer.